

ASX Code: GSS
26 November 2020

Genetic Signatures to present at Bell Potter Healthcare conference

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”), has been invited to present at the Bell Potter Virtual Healthcare Conference 2020 today. The Company’s presentation entitled “*Update from Genetic Signatures Sales Directors*” comprises pre-recorded videos from John Buckels, Director, Sales & Support Europe, and Derek Joesting, Director of Sales, North America. These may be accessed via the link below.

<https://geneticsignatures.com/au/investors/presentations/>

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley
Chief Financial Officer

peter.manley@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures’ proprietary MDx **3base**[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.